Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06997068 · ClinicalTrials.gov registry record · Phase 2
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
A Phase 2 study of Metastatic Oral Cavity Carcinoma and Recurrent Oral Cavity Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06997068 is a Phase 2 study of Metastatic Oral Cavity Carcinoma and Recurrent Oral Cavity Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06997068, a Phase 2 study of Metastatic Oral Cavity Carcinoma and Recurrent Oral Cavity Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating oral cavity cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving the combination of methotrexate, erlotinib, and celecoxib may be feasible, safe, and effective in treating rural Midwest patients with recurrent/metastatic oral cavity cancer.
Conditions Studied
Interventions
- DRUG Celecoxib
- PROCEDURE Imaging Procedure
- OTHER Interview
- DRUG Methotrexate
- DRUG Erlotinib Hydrochloride
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06997068
The ClinicalTrials.gov registry entry for NCT06997068 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Oral Cavity Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Celecoxib is the first listed.
NCT06997068 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06997068 about?
NCT06997068 is a clinical study titled "Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population". This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating oral cavity cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in...
What is the current status of trial NCT06997068?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-07-09. Estimated completion is 2028-06-30.
What conditions does trial NCT06997068 study?
This clinical trial studies the following conditions: Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8.
What interventions are being tested in trial NCT06997068?
The interventions under investigation include: Celecoxib (DRUG), Imaging Procedure (PROCEDURE), Interview (OTHER), Methotrexate (DRUG), Erlotinib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06997068?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06997068 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Metastatic Oral Cavity Carcinoma
All registered trials for this condition
Recurrent Oral Cavity Carcinoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.